—empagliflozin, canagliflozin and dapagliflozin, glucagon-like peptide-1 receptor agonists (GLP-1Ras)—liraglutide, semaglutide has revealed significant glucose independent reduction in (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and heart failure requiring hospitalization for unstable angina or heart failure (HF) [14,15,16,17]. This evidence concerns the gene GLP1R and heart failure.